Week in Review: China's Creat to Restructure $1.5 Billion Biotest Takeover

Deals and Financings   China 's Creat Group will attempt to restructure its $1.5 billion offer to acquire Biotest, a German blood plasma company, after US regulators nixed the deal; Valeant Pharma closed its $190 million sale of California-based Obagi Medical Products to a group that includes China Regenerative Medicine; Zhejiang Huahai Pharma acquired China rights to an immuno-oncology candidate discovered by Eutilex of South Korea in a $65 million agreement that included a $30 million investment in Eutilex; EOC Pharma Group of Shanghai , an oncology spin-out from China in-licensing company Eddingpharm, closed a $32 million B funding round;  AnchorDx Corp of Guangzhou raised $28 million in a Series B round to develop precision oncology products using next-generation sequencing technology; Exicure, a Chicago developer of nucleic acid drugs, closed a $11.2 million funding led by Yantai-based Luye Pharma; Ark Biosciences of Shanghai partnered with the California Institute for Biomedical Research of La Jolla to develop novel therapies for COPD and other lung diseases;   Company News Sweden 's Genovis signed a China distribution agreement with Shanghai Titan Scientific for its portfolio of enzymes that are used in making biologic drugs; Cellular Biomedicine held an official opening for its new Shanghai CAR-T manufacturing facility, located in Zhangjiang High-Tech Park .  Stock Symbols: (DE: BIOG) (NYSE: VRX) (HK: 2186) (NSDQ: CBMG) Share this with colleagues: // //